PT  - JOURNAL ARTICLE
AU  - Olimpia E. Curran
AU  - Michael T. C. Poon
AU  - Louise Gilroy
AU  - Antonia Torgersen
AU  - Colin Smith
AU  - Wael Al-Qsous
TI  - MYD88 L265P mutation in primary central nervous system lymphoma is associated with better survival: A single centre experience
AID  - 10.1101/2020.09.06.20185827
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.06.20185827
4099  - http://medrxiv.org/content/early/2020/09/09/2020.09.06.20185827.short
4100  - http://medrxiv.org/content/early/2020/09/09/2020.09.06.20185827.full
AB  - Background The Myeloid differentiation primary response gene (MYD88) mutation in primary central nervous system lymphomas (PCNSL) may be associated with unfavourable prognosis, however the evidence remains limited. We aimed to comprehensively characterise PCNSLs by integration of clinicopathological, molecular, treatment and survival data.Methods We retrospectively identified and validated 57 consecutive patients with PCNSLs according to the 2017 WHO classification of lymphoid neoplasms over a 13-year period. Formalin-fixed paraffin-embedded tumour samples underwent real-time allele-specific polymerase chain reaction assay to detect MYD88 mutation. We used multivariable Cox regression for survival analysis including age, treatment, and MYD88 as covariates. We searched the literature for studies reporting demographics, treatment, MYD88 and survival of PCNSL patients, and incorporated individual-patient data into our analyses.Results The median age was 66 years and 56% were women. All 57 patients had non-germinal PCNSL and the majority (81%) received either single or combined therapies. There were 46 deaths observed over the median follow-up of 10 months. MYD88 mutation status was available in 41 patients of which 36 (88%) were mutated. There was an association between MYD88 mutation and better survival in the multivariable model (hazard ratio [HR] 0.34; 95% confidence interval [CI] 0.12-0.95; p=0.039) but not in a univariable model. After incorporating additional 18 patients from the literature, this association was reproducible (HR 0.31, 95% CI 0.13-0.77, p=0.012).Conclusions Adjusting for confounders, MYD88 mutation is associated with better survival. While further validation is warranted, identification of MYD88 mutation can identify patients who may benefit from novel targeted therapies.Key pointsMYD88 mutation is common in PCNSLs.MYD88 mutation in PCNSLs is associated with better survival after adjusting for age at diagnosis and treatment.Identification of MYD88 mutation in PCNSLs can identify patients who may benefit from novel targeted therapies and enhance survival.Importance of the study PCNSLs are rare and associated with lower survival than their systemic counterparts. The emergence of new molecular targets in PCNSLs, such as mutations in the MYD88 gene, offers hope for more effective therapeutics. Few studies have investigated the association between MYD88 mutation and survival. These studies, however, are limited by inconsistent inclusion of clinical variables and suboptimal analytic approach, such as overfitting model or incomplete adjustment for important confounders. Our study integrates treatment, molecular and survival data for 57 patients diagnosed with PCNSL. We demonstrate that without adequate adjustment for confounders such as age at diagnosis and treatment, MYD88 mutation does not affect survival. However, a multivariable survival model including these variables shows MYD88 mutation to be associated with better survival. While further validation of this association is warranted, our findings suggest that identification of MYD88 mutation can identify patients who may benefit from novel targeted therapies and enhance survival.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMTCP is supported by Cancer Research UK Brain Tumour of Excellence Award (C157/A27589).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethical approval for this study was waived by the Tissue Governance committee of the South East Scotland SAHSC BioResource.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that all data underlying the findings are available and will be shared with the research community upon request.